Reply to: Individualized Diagnostic and Prognostic Models for Psychosis Risk Syndromes: Do Not Underestimate Antipsychotic Exposure

Abstract

We thank the authors for their interest in our meta-analysis on diagnostic and prognostic models for clinical high risk (CHR) individuals (1). Raballo et al. (2) discuss the critical issue of antipsychotics (APs) within the CHR paradigm and its potential role in predictive models for detection of transition to psychosis. Specifically, Raballo et al. highlighted three points: 1) the majority of predictive models lack information about APs in high-risk cohorts, 2) baseline APs could influence the clinical presentation of individuals and/or modify the longitudinal development of their symptoms, and 3) the presence of APs at baseline in CHR individuals might signal higher psychopathological severity and thus be a proxy for higher risk of developing psychosis.